Home / Insights / ADHD Medications: Stimulants, Nonstimulants, and What Treatment Can Actually Do
ADHD Treatment
ADHD Medications: Stimulants, Nonstimulants, and What Treatment Can Actually Do
ADHD medication is one of the most studied treatments in psychiatry, yet public discussion often swings between two extremes: “medication fixes everything” and “medication should never be used.” The evidence supports a more precise view.
10–12 minute read
What medication is designed to do
ADHD medications are intended to reduce core symptoms such as inattention, hyperactivity, and impulsivity and to improve functional performance while the medication is active. The goal is not to change personality or eliminate every difficulty associated with ADHD.
Treatment success is better judged by real outcomes — completing work, reducing disruptive behavior, improving driving or organization, lowering conflict, or making school participation more manageable — than by symptom scores alone.
Key Fact
The FDA recognizes both stimulant and nonstimulant medications for ADHD. In July 2026, centanafadine extended-release (Simtriyo) became a newly approved option for adults and pediatric patients age 6+ weighing at least 20 kg.
Stimulants remain a major first-line option
Methylphenidate- and amphetamine-based medications have strong evidence for short-term symptom reduction in many children, adolescents, and adults. Formulations differ in duration, release profile, delivery system, and dosing schedule.
Stimulants can cause decreased appetite, insomnia, abdominal discomfort, headache, increased heart rate or blood pressure, and other adverse effects. They also carry risks of misuse, addiction, overdose, and diversion, which is why FDA labeling includes prominent safety warnings and clinicians assess individual risk.
Nonstimulants broaden the options
FDA-approved nonstimulant options include atomoxetine, extended-release guanfacine, extended-release clonidine, and viloxazine extended release for indicated age groups. In July 2026, the FDA also approved centanafadine extended-release (Simtriyo) for ADHD in adults and pediatric patients age 6 and older who weigh at least 20 kg.
Nonstimulants may be considered when stimulants are ineffective, poorly tolerated, contraindicated, or not preferred. They differ in onset, side-effect profile, dosing, and evidence base, so “nonstimulant” does not describe a single type of treatment.
| Category | Examples | General considerations |
|---|---|---|
| Stimulants | Methylphenidate and amphetamine formulations | Strong short-term efficacy; appetite, sleep, cardiovascular and misuse risks require monitoring |
| Selective norepinephrine reuptake inhibitor | Atomoxetine | Noncontrolled; slower onset than stimulants; specific warnings and monitoring apply |
| Alpha-2 agonists | Guanfacine ER, clonidine ER | May help hyperactivity/impulsivity; sedation and blood-pressure effects can occur |
| Other nonstimulants | Viloxazine ER; centanafadine ER | Different mechanisms, indications, warnings, and age limits |
New does not automatically mean better
A newly approved medication expands choice, but it does not automatically replace established treatments. Clinicians consider comparative evidence, individual risks, age, comorbid conditions, prior response, convenience, access, and patient preference.
Centanafadine, for example, has its own prescribing information, warnings, age and weight limitations, and monitoring considerations. Its approval is clinically important, but longer-term real-world experience will continue to develop.
Monitoring is part of treatment
Before and during medication treatment, clinicians commonly review cardiovascular history, blood pressure, heart rate, growth in children, appetite, sleep, mood, tics when relevant, and the possibility of misuse or diversion. The exact monitoring plan depends on the medication and patient.
FDA strengthened class-wide stimulant warnings in 2023 regarding misuse, abuse, addiction, overdose, and sharing medications. In 2025, FDA also required expanded labeling for extended-release stimulants about increased weight-loss risk and other adverse reactions in children younger than 6 years.
What This Means
Medication can be highly effective for core symptoms, but it does not replace sleep, behavioral supports, school/work accommodations, or treatment of coexisting conditions.
Behavioral and environmental treatment still matters
Medication cannot create organizational systems, repair sleep deprivation, teach parenting strategies, provide school accommodations, or treat every coexisting anxiety, learning, or mood problem. Comprehensive care may include parent training in behavior management, school-based interventions, psychotherapy or cognitive-behavioral strategies, and practical environmental supports.
For preschool-aged children, behavior therapy — particularly parent training — is recommended before medication in standard U.S. guidance. Recommendations differ by age and clinical context.
Finding the right treatment is an iterative process
People vary considerably in response and tolerability. A medication that works well for one person may be ineffective or uncomfortable for another. Treatment often involves systematic trials, dose adjustment, monitoring, and periodic reassessment.
The objective is the lowest-burden plan that produces meaningful functional benefit with acceptable risks. Medication decisions should be individualized with a qualified clinician rather than based on social-media anecdotes or another person’s prescription.
Frequently asked questions
Are stimulants addictive when prescribed for ADHD?
Prescription stimulants have abuse and addiction potential and are Schedule II controlled substances in the United States. Appropriate prescribing, storage, monitoring, and not sharing medication are essential.
Do ADHD medications “cure” ADHD?
No. They treat symptoms and can improve functioning, but benefits generally depend on ongoing treatment and do not erase the underlying neurodevelopmental condition.
Is the newest medication automatically the best choice?
No. Approval adds an option, not a universal preference. Selection depends on evidence, patient characteristics, risks, prior response, and practical factors.
What to remember
Medication can substantially reduce ADHD symptoms for many people, but good treatment is broader than choosing a pill. Benefits, adverse effects, monitoring, age, comorbidity, misuse risk, behavioral supports, and patient goals all matter. The most effective plan is individualized and periodically reassessed as life demands change.
Related Insights
Adult ADHD: Why It Can Be Missed Until Later in Life
Why a lifelong pattern often becomes recognizable only in adulthood. Read more →
How ADHD Affects Attention, Motivation, and Executive Function
Why focus, motivation, and time management can be so inconsistent. Read more →
ADHD, Anxiety, Depression, and Sleep: Why Symptoms Overlap
How clinicians distinguish overlapping symptoms and identify comorbidity. Read more →
Selected References
FDA. Treating and Dealing with ADHD.
FDA. Prescription Stimulant Medications: Drug Safety Information.
FDA. Drug Safety Communication on expanded labeling for extended-release stimulants in children younger than 6 years. 2025/2026.
FDA. Simtriyo (centanafadine) Prescribing Information and Approval Letter. July 24, 2026.
CDC. Treatment of ADHD. Updated June 2026.
AAP. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents. Pediatrics. 2019.
Cortese S, et al. Comparative efficacy and tolerability of medications for ADHD. Lancet Psychiatry. 2018;5:727-738.